As Senator, I would ensure that real free market principles are applied to fix this problem.
As senator, ensure that real free market principles are applied to fix the problem.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
On May 13, 2026, Chairman Rand Paul convened a full committee hearing and said the committee would hear whistleblower testimony about government concealment and lack of transparency surrounding COVID-19 origins. He framed the hearing as exposing buried or softened intelligence conclusions and ongoing secrecy within agencies.
legacy_unverified · Source version not recorded · locator unknown
In the latest 'Waste Report,' Paul criticized NSF spending on a study of standards and measurement and highlighted federal spending on the Office of Weights and Measures. The page is presented as an ongoing catalog of wasteful spending and says government measurement policy had already been pushed by free-market forces historically.
legacy_unverified · Source version not recorded · locator unknown
The Senate Daily Press schedule for the lookback window said the Senate convened for a pro forma session on September 8, 2026, with no business conducted, expected another pro forma session on September 10 with no business expected, and listed the next vote for September 14, 2026.
legacy_unverified · Source version not recorded · locator unknown
Paul's office said the Senate HELP Committee unanimously advanced his Expedited Access to Biosimilars Act, which would streamline biosimilar approvals by eliminating costly and redundant clinical study requirements, increase market competition, lower drug prices, and require FDA justification for extra study requirements.
Assessments
Paul made repeated free-market health-care efforts as a senator, including repeal advocacy, association health plan proposals, and the Expedited Access to Biosimilars Act advancing from committee in 2026. Those actions materially show effort, but the promised outcome was to apply real free-market principles to fix the health-care problem, and the evidence does not show a broad enacted or implemented fix. Committee advancement and advocacy are not delivery of the promised policy result.
The promise is broad and low-specificity, but it implies delivering a policy fix through real free-market principles as a U.S. senator. The supplied evidence shows oversight, criticism of federal spending, and continued advocacy consistent with Rand Paul's limited-government/free-market posture, not enactment of a concrete free-market policy fix. His federal Senate service gives him candidate credit for serious attempts and advocacy during his tenure, but the promised outcome is not shown as fulfilled.